Sponsored by:

Molecular Imaging: Page 270

Shine Medical reaches Mo-99 milestone
By AuntMinnie.com staff writers
Medical isotope firm Shine Medical Technologies announced it has reached a milestone in its development program with Phoenix Nuclear Labs by successfully producing 3 x 1011 neutrons per second with a deuterium-deuterium fusion reaction.
May 1, 2013
Navidea launches Lymphoseek in U.S.
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has launched its Lymphoseek nuclear medicine imaging agent in the U.S.
April 30, 2013
Lantheus to proceed with flurpiridaz F-18 program
By AuntMinnie.com staff writers
Contrast agent developer Lantheus Medical Imaging plans to proceed with a phase III program for its flurpiridaz F-18 PET radiopharmaceutical, based on an interim analysis of data from its first phase III study.
April 30, 2013
Philips sells 1st PET/MRI to children's hospital
By AuntMinnie.com staff writers
Texas Children's Hospital announced it will be the first children's hospital in the U.S. to use a PET/MRI scanner (Philips Healthcare).
April 29, 2013
GE, Eisai to partner on PET Alzheimer's agent
By AuntMinnie.com staff writers
GE Healthcare has announced a research collaboration with Japanese pharmaceutical firm Eisai.
April 24, 2013
Navidea raises $5.1M in common stock sale
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has raised $5.1 million in an underwritten sale of common stock.
April 23, 2013
Eli Lilly buys PET drug candidates from Siemens
By AuntMinnie.com staff writers
Pharmaceutical firm Eli Lilly has acquired two investigational PET drug candidates from Siemens Healthcare designed to image early signs of Alzheimer's disease.
April 18, 2013
Navidea touts JNM study on amyloid imaging candidate
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals is highlighting a peer-reviewed study that assessed the performance of its fluorine-18-labeled amyloid imaging candidate.
April 18, 2013
Cell>Point touts cardiac imaging agent trial results
By AuntMinnie.com staff writers
Radiopharmaceutical developer Cell>Point said that results from phase I and IIa studies of its technetium-99m-labeled ethylenedicysteine-glucosamine (99mTc-EC-G) nuclear imaging contrast agent have been favorable for evaluating the presence and severity of coronary artery disease.
April 9, 2013
PET/CT predicts early breast cancer response to chemo
By Wayne Forrest
By using FDG-PET/CT, physicians will be in a better position to noninvasively predict a breast cancer patient's response to treatment after two cycles of neoadjuvant chemotherapy, helping them decide on the next course of action, concluded a study from Germany.
April 9, 2013
Oak Ridge researchers target awake SPECT imaging
By AuntMinnie.com staff writers
Researchers at the Oak Ridge National Laboratory are working to develop an awake SPECT imaging method that they believe shows promise for providing clear images of the brains of children, the elderly, and people with Parkinson's and other diseases without using restraints.
April 8, 2013
AuntMinnie.com Molecular Imaging Insider
By Wayne Forrest
April 4, 2013
Previous Page
Page 270 of 612
Next Page